Accueil   Diary - News   All news Collaboration between Gustave Roussy Cancer Centre and Orphelia Pharma

Collaboration between Gustave Roussy Cancer Centre and Orphelia Pharma

 

ORPHELIA Pharma executes a collaboration and license agreement with Gustave Roussy cancer centre for the development of the first pediatric formulation of temozolomide

 

Paris and Lyon, July 2nd, 2019 – ORPHELIA Pharma, a French biopharmaceutical company dedicated to the development and marketing of paediatric drugs in the fields of oncology and neurology, announces today that a collaboration and license agreement has been executed with Gustave Roussy, the leading European Comprehensive Cancer Centre for the development of Kimozo®, the first paediatric formulation of temozolomide.

 

Read the press release